Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study
Year: 2017
Type: conference-abstract
Source: Blood
Authors: Courtney D. DiNardo, Stephane De Botton, Eytan M. Stein, Gail J. Roboz, Alice S. Mims, Daniel A. Pollyea, Ronan T. Swords, Jessica K. Altman, Robert H. Collins, Gabriel N. Mannis, Geoffrey L. Uy, Will Donnellan, Arnaud Pigneux, Amir T. Fathi, Anthony S. Stein, Harry P. Erba, Gabrielle T. Prince, James M. Foran, Elie Traer, Robert K. Stuart, Martha L. Arellano, James L. Slack, Mikkael A. Sekeres, Katharine Yen, Stephanie M. Kapsalis, Hua Liu, Meredith Goldwasser, Sam Agresta, Eyal C. Attar, Martin S. Tallman, Richard M. Stone, Hagop M. Kantarjian
Institutions: The University of Texas MD Anderson Cancer Center, Institut Gustave Roussy, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, The Ohio State University Wexner Medical Center, The Ohio State University, University of Colorado Cancer Center, University of Colorado Denver, University of Miami, Sylvester Comprehensive Cancer Center, Northwestern University, The University of Texas Southwestern Medical Center, University of California, San Francisco, Washington University in St. Louis, Sarah Cannon, Centre Hospitalier Universitaire de Bordeaux, Massachusetts General Hospital, City Of Hope National Medical Center, University of Alabama, University of Alabama at Birmingham, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Mayo Clinic in Florida, Oregon Health & Science University, OHSU Knight Cancer Institute, Medical University of South Carolina, MUSC Hollings Cancer Center, Emory University, Mayo Clinic in Arizona, Mayo Clinic Hospital, Mayo Clinic Comprehensive Cancer Center (Arizona), Cleveland Clinic, Agios Pharmaceuticals (United States), Dana-Farber Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2783175942